News

Swiss neurotech Indivi buys Imperial spin-out Cogitat for brain monitoring

What's the deal? Basel-based neurotech Indivi has acquired CogitatDealroom has a profile for this one. Try Dealroom →, an Imperial College London spin-out that builds deep learning models to decode cognitive function from EEG brain signals. The deal value was undisclosed. Indivi helps biopharmaceutical sponsors design smaller early-phase trials and detect treatment effects.

What's the endgame? The acquisition folds Cogitat's EEG foundation model, NeuroRVQ, into Indivi's platform, which already runs smartphone-based motor and cognitive assessments across Parkinson's, multiple sclerosis, and Alzheimer's. The goal: detect early signs of treatment response in Alzheimer's and other neurological conditions.

What's the product? NeuroRVQ decodes brainwaves and is designed to work on any brain and any device without individual training. It preserves fine, fast-changing detail that most models discard. Indivi aims to use this to detect subtler signs of disease and treatment response than existing methods allow.

What they're saying: "Cogitat's EEG foundation model changes that, decoding brain activity and revealing signals far closer to the underlying biology than ever before," said Guilhem Dupont, Indivi's chief executive officer and founder. Cogitat chief executive officer and founder Allan Ponniah said the model targets "one of neuroscience's biggest translational gaps: the failure to detect early changes in brain biology that predict whether a treatment or product will actually work."

Why now? The move follows recent investor backing. Indivi raised US$13.8M in November 2025, and Infosys Innovation Fund became a strategic investor in 2026 to support scaling the platform.

What could go wrong? The announcement does not establish that NeuroRVQ can improve clinical-trial outcomes. Its value will depend on validation in patient studies and whether it detects meaningful treatment effects better than existing measures.

The signal: The deal fits a wider push to combine AI with EEG and other digital measures. Beacon Biosignals has expanded through acquisitions, while Cumulus Neuroscience recently began trials testing at-home digital and physiological biomarkers in Alzheimer's and other conditions.

Read more: Tech.eu

Image credit: Generated with Gemini

More top stories